Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Andriana I Papaioannou, Evangelia Fouka, Konstantinos Bartziokas, Maria Kallieri, Angelos Vontetsianos, Konstantinos Porpodis, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2023) Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission. Expert Review of Respiratory Medicine 17:6, pages 481-493.
Read now
Read now
Didier Cataldo, Renaud Louis, Alain Michils, Rudi Peché, Charles Pilette, Florence Schleich, Vincent Ninane & Shane Hanon. (2021) Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. Journal of Asthma 58:4, pages 448-458.
Read now
Read now
Cristoforo Incorvaia, Marina Mauro, Elena Makri, Gualtiero Leo & Erminia Ridolo. (2018) Two decades with omalizumab: what we still have to learn. Biologics: Targets and Therapy 12, pages 135-142.
Read now
Read now
Daniel Colodenco, Oscar Palomares, Carlos Celis, Alan Kaplan & Christian Domingo. (2018) Moving toward consensus on diagnosis and management of severe asthma in adults. Current Medical Research and Opinion 34:3, pages 387-399.
Read now
Read now
Maria Kallieri, Andriana I. Papaioannou, Evgenia Papathanasiou, Polyxeni Ntontsi, Spyridon Papiris & Stelios Loukides. (2017) Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgraduate Medicine 129:6, pages 598-604.
Read now
Read now
Maxime Luu, Marc Bardou, Philippe Bonniaud & Françoise Goirand. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1503-1511.
Read now
Read now
Divya Reddy & Frederic F. Little. (2013) Glucocorticoid-resistant asthma: more than meets the eye. Journal of Asthma 50:10, pages 1036-1044.
Read now
Read now
Massimo Caruso, Emanuele Crisafulli, Shirin Demma, Stephen Holgate & Riccardo Polosa. (2013) Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma. Expert Opinion on Biological Therapy 13:3, pages 393-402.
Read now
Read now
Zenon Siergiejko, Ewa Świebocka, Nicola Smith, Clare Peckitt, Jo Leo, Guy Peachey & Robert Maykut. (2011) Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Current Medical Research and Opinion 27:11, pages 2223-2228.
Read now
Read now
Articles from other publishers (28)
Christian Domingo, Rosa M. Mirapeix, Francisco-Javier González-Barcala, Carles Forné & Felip García. (2023) Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study. Drugs 83:12, pages 1111-1123.
Crossref
Crossref
C. Cisneros-Serrano, M.J. Rial, A. Gómez-Bastero-Fernández, J.M. Igea, A. Martínez-Meca, L.C. Fernández-Lisón, V. López-Carrasco, E. Villamañán-Bueno, M.J. Plá-Martí & E. Chiner. (2023) Spanish multidisciplinary consensus on the characteristics of severe asthma patients on biologic treatment who are candidates for at-home administration. Revista Clínica Española (English Edition) 223:3, pages 154-164.
Crossref
Crossref
C. Cisneros-Serrano, M.J. Rial, A. Gómez-Bastero-Fernández, J.M. Igea, A. Martínez-Meca, L.C. Fernández-Lisón, V. López-Carrasco, E. Villamañán-Bueno, M.J. Plá-Martí & E. Chiner. (2023) Consenso multidisciplinar español sobre las características de los pacientes con asma grave en tratamiento con biológicos susceptibles de pasar a tratamiento domiciliario. Revista Clínica Española 223:3, pages 154-164.
Crossref
Crossref
Nicola A. Hanania, Robert Niven, Pascal Chanez, Deschildre Antoine, Pascal Pfister, Lorena Garcia Conde & Xavier Jaumont. (2022) Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal 15:10, pages 100695.
Crossref
Crossref
Mona Al Ahmad, Lilia Margarita Borboa Olivares, Alexandre Pinto Cardoso, Wagih Djazmati, Miguel Angel Vinuesa, María de Jesús García Domínguez, Alcindo Cerci Neto, Luis Ugalde Gamboa, Jason K. Lee, Nadine Pinho & Paolo Tassinari. (2022) Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study. The Open Respiratory Medicine Journal 16:1.
Crossref
Crossref
Francisco Javier Alvarez-Gutiérrez, Marina Blanco-Aparicio, Francisco Casas-Maldonado, Vicente Plaza, Francisco Javier González-Barcala, José Ángel Carretero-Gracia, Manuel Castilla-Martínez, Carolina Cisneros, David Diaz-Pérez, Christian Domingo-Ribas, Eva Martínez-Moragon, Xavier Muñoz, Alicia Padilla-Galo, Miguel Perpiñá-Tordera & Gregorio Soto-Campos. (2022) Documento de consenso de asma grave en adultos. Actualización 2022. Open Respiratory Archives 4:3, pages 100192.
Crossref
Crossref
Christian Domingo, Jorge F. Maspero, Mario Castro, Nicola A. Hanania, Linda B. Ford, David M.G. Halpin, David J. Jackson, Nadia Daizadeh, Michel Djandji, Colin P. Mitchell, Nora Crikelair, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe & Benjamin Ortiz. (2022) Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. The Journal of Allergy and Clinical Immunology: In Practice 10:7, pages 1835-1843.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Andriana I. PapaioannouMyrto MplizouKonstantinos PorpodisEvangelia FoukaEleftherios ZervasKonstantinos SamitasMiltiadis MarkatosPetros Bakakos, Spyridon PapirisMina GagaDespoina PapakostaStelios Loukides. (2021) Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. Allergy and Asthma Proceedings 42:3, pages 235-242.
Crossref
Crossref
Wei-Chang Huang, Pin-Kuei Fu, Ming-Cheng Chan, Chun-Shih Chin, Wen-Nan Huang, Kuo-Lung Lai, Jiun-Long Wang, Wei-Ting Hung, Yi-Da Wu, Chia-Wei Hsieh, Ming-Feng Wu, Yi-Hsing Chen & Jeng-Yuan Hsu. (2021) The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment. Journal of Clinical Medicine 10:4, pages 707.
Crossref
Crossref
Christian Domingo, Xavier Pomares, Anisi Morón & Ana Sogo. (2020) Dual Monoclonal Antibody Therapy for a Severe Asthma Patient. Frontiers in Pharmacology 11.
Crossref
Crossref
Francisco Javier Álvarez-Gutiérrez, Marina Blanco-Aparicio, Vicente Plaza, Carolina Cisneros, Juan Luis García-Rivero, Alicia Padilla, Luis Pérez-de Llano, Miguel Perpiñá & Gregorio Soto-Campos. (2020) Documento de consenso de asma grave en adultos. Actualización 2020. Open Respiratory Archives 2:3, pages 158-174.
Crossref
Crossref
O. M. Kurbacheva & M. A. Galitskaya. (2019) The place of Omalizumab in the treatment of allergic diseases. Medical Council:15, pages 38-49.
Crossref
Crossref
Babak Aberumand & Anne K. Ellis. (2019) Asthma and the Biologics Revolution, Part 1: Here and Now. Current Treatment Options in Allergy 6:4, pages 447-467.
Crossref
Crossref
Paraskevi Katsaounou, Roland Buhl, Guy Brusselle, Pascal Pfister, Rafael Martínez, Ulrich Wahn & Jean Bousquet. (2019) Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine 150, pages 51-62.
Crossref
Crossref
Herrera-García José Carlos. (2018) Use of omalizumab in women Mexican patients diagnosed with moderate to severe non-atopic asthma: an observational real-life study in a university hospital. Journal of Lung, Pulmonary & Respiratory Research 5:5, pages 138-141.
Crossref
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, María José Amengual, Concepción Montón, Ana Sogo & Rosa M. Mirapeix. (2018) A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. British Journal of Clinical Pharmacology 84:2, pages 339-348.
Crossref
Crossref
Christian Domingo. (2017) Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. Drugs 77:16, pages 1769-1787.
Crossref
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, Núria Rudi, Ana Sogo, Ignacio Dávila & Rosa Mirapeix. (2017) Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. International Journal of Molecular Sciences 18:3, pages 521.
Crossref
Crossref
Riccardo Polosa, Salvatore Bellinvia, Massimo Caruso, Rosalia Emma, Angela Alamo, Marek Leszek Kowalski & Christian Domingo. (2014) Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial. Trials 15:1.
Crossref
Crossref
C. Domingo, X. Pomares, M.-J. Amengual & M. Ollert. (2014) Successful Withdrawal of Omalizumab in a Patient with Severe Asthma: Free IgE as a Possible Biomonitor. European Journal of Inflammation 12:2, pages 389-393.
Crossref
Crossref
Christian Domingo. (2014) Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?. Drugs 74:5, pages 521-533.
Crossref
Crossref
Massimo Caruso, Emanuele Crisafulli, Raffaella Lizzio & Riccardo Polosa. (2013) Biologic therapy for atopic asthma and beyond. Current Opinion in Allergy & Clinical Immunology 13:6, pages 677-685.
Crossref
Crossref
Manel Luján, Xavier Gallardo, María José Amengual, Montserrat Bosque, Rosa M. Mirapeix & Christian Domingo. (2013) Prevalence of Bronchiectasis in Asthma according to Oral Steroid Requirement: Influence of Immunoglobulin Levels. BioMed Research International 2013, pages 1-7.
Crossref
Crossref
Riccardo Polosa & Thomas Casale. (2012) Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discovery Today 17:11-12, pages 591-599.
Crossref
Crossref
Riccardo Polosa, Gabriella Papale & Stephen T HolgateGabriella PapaleRiccardo Polosa. 2012. Advances in Asthma Management. Advances in Asthma Management
182
195
.
C. Domingo, A. Moreno & R. Mirapeix. (2011) Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids. Internal Medicine Journal 41:7, pages 525-536.
Crossref
Crossref
Salvatore Clienti, Jaymin B. Morjaria, Elisa Basile & Riccardo Polosa. (2011) Monoclonal Antibodies for the Treatment of Severe Asthma. Current Allergy and Asthma Reports 11:3, pages 253-260.
Crossref
Crossref